David T Fikstad
Land Surveyors in Salt Lake City, UT

6365178, Apr 2, 2002

Jan 17, 2001

09/764040

Srinivasan Venkateshwaran - Salt Lake City UT
David Fikstad - Salt Lake City UT
Charles D. Ebert - Salt Lake City UT

Watson Pharmaceuticals, Inc. - Corona CA

A61K 970

424449, 424447, 424448

A method of making a pressure sensitive matrix patch for transdermal delivery of a drug is disclosed. The method includes the steps of dissolving a hydrophilic salt form of the drug in the water phase of an aqueous dispersion of a hydrophobic pressure sensitive adhesive, casting the resulting mixture as a thin film, and evaporating the water. The physical stability of the drug in the film is excellent, and crystallization of the drug is inhibited. A method of increasing the transdermal flux of an acidic drug is also disclosed.

2003023, Dec 25, 2003

May 22, 2003

10/444935

Mahesh Patel - Salt Lake City UT, US
David Fikstad - Salt Lake City UT, US
Huiping Zhang - Salt Lake City UT, US
Chandrashekar Gilyar - Salt Lake City UT, US

A61K031/56, A61K031/355, A61K031/122

514/171000, 514/458000, 514/682000

Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs, particularly steroids, are provided. The pharmaceutical compositions include a therapeutically effective amount of a hydrophobic drug, preferably a steroid; a solubilizer, preferably a vitamin E substance; and a surfactant. The synergistic effect between the hydrophobic drug and the vitamin E substance results in a pharmaceutical formulation with improved dispersion of both the active agent and the solubilizer. As a result of the improved dispersion, the pharamaceutical composition has improved bioavailability upon administration. Methods of improving the bioavailability of hydrophobic drugs administered to a patient are also provided.

5912009, Jun 15, 1999

Oct 29, 1997

8/959944

Srinivasan Venkateshwaran - Salt Lake City UT
David Fikstad - Salt Lake City UT
Sonal R. Patel - Sandy UT

TheraTech, Inc. - Salt Lake City UT

A61F 1302

424448

A transdermal drug delivery system which enhances the delivery of the drug comprises a composition containing, as an enhancer, one or more C. sub. 6 to C. sub. 22 fatty acid esters of glycolic acid and its salts. These compositions are made up of a safe and effective amount of an active pharmaceutical permeant contained in a penetration-enhancing vehicle comprising, 0. 25 to 50% w. of the fatty acid glycolic acid ester enhancer in a suitable carrier vehicle. These fatty acid glycolic acid ester enhancers may be used in various carrier vehicles to enhance the transdermal delivery of active permeants in either free form or used in an occlusive device, particularly in a transdermal patch in matrix or reservoir form. When used in matrix patch form, the fatty acid glycolic acid ester enhancers and permeants are incorporated into a biocompatible adhesive. When used in a reservoir type patch, the permeant and fatty acid glycolic acid ester enhancers are incorporated into a carrier fluid of controlled viscosity such as a gel or ointment preferably containing a lower alkanol and water.

2007028, Dec 6, 2007

Jun 6, 2006

11/448597

Shanthakumar Tyavanagimatt - Salt Lake City UT, US
David Fikstad - Salt Lake City UT, US
Chandrashekar Giliyar - Salt Lake City UT, US
Mahesh Patel - Salt Lake City UT, US
Srinivasan Venkateshwaran - Salt Lake City UT, US

A61K 31/5415

5142265

Methods and compositions for delivering a meloxicam compound are disclosed and described. In one aspect, a method may include perorally administering to a subject a therapeutically effective amount of a meloxicam compound that provides a meloxicam plasma concentration within 1 hour which is at least about 40% of the maximum plasma concentration attained by the formulation. In another aspect, a composition may include a therapeutically effective amount of a meloxicam compound in a pharmaceutically acceptable carrier including at least one of an alkalizer or a solubilizer, with the meloxicam compound having a solubility in the carrier that is greater than about 1.0 mg/gm.

2006000, Jan 5, 2006

May 4, 2005

11/122788

David Fikstad - Salt Lake City UT, US
Srinivasan Venkateshwaran - Salt Lake City UT, US
Chandrashekar Giliyar - Salt Lake City UT, US
Mahesh Patel - Salt Lake City UT, US

A61K 31/724, A61K 31/401, A61K 31/366, A61K 9/22, A61K 31/355, A61K 31/225

424468000, 514423000, 514460000, 514458000, 514058000, 514548000

Pharmaceutical compositions with synchronized solubilizer release as well as various methods associated therewith, are disclosed and described. More specifically, the aqueous solubility of a drug is enhanced by synchronized release of a solubilizer.

2005009, May 5, 2005

Nov 3, 2003

10/700838

David Fikstad - Salt Lake City UT, US
Srinivasan Venkateshwaran - Salt Lake City UT, US
Chandrashekar Giliyar - Salt Lake City UT, US
Mahesh Patel - Salt Lake City UT, US

A61K031/724, A61K031/426, A61K031/355

514369000, 514423000, 514469000, 514458000, 514058000

Pharmaceutical compositions with synchronized solubilizer release as well as various methods associated therewith, are disclosed and described. More specifically, the aqueous solubility of a drug is enhanced by synchronized release of a solubilizer.

5952000, Sep 14, 1999

Oct 29, 1997

8/959946

Srinivasan Venkateshwaran - Salt Lake City UT
David Fikstad - Salt Lake City UT
Sonal R. Patel - Sandy UT

TheraTech, Inc. - Salt Lake City UT

A61F 1302

424448

A transdermal drug delivery system which enhances the delivery of the drug comprises a composition containing, as an enhancer, one or more C. sub. 6 to C. sub. 22 fatty acid esters of a lactic acid salt. These compositions are made up of a safe and effective amount of an active pharmaceutical permeant contained in a penetration-enhancing vehicle comprising, 0. 25 to 50% w. of the fatty acid ester of a lactic acid salt enhancer in a suitable pressure sensitive adhesive carrier vehicle formed from and aqueous emulsion based pressure sensitive adhesive.

2005009, May 5, 2005

Jan 23, 2004

10/764016

David Fikstad - Salt Lake City UT, US
Srinivasan Venkateshwaran - Salt Lake City UT, US
Chandrashekar Giliyar - Salt Lake City UT, US
Mahesh Patel - Salt Lake City UT, US

A61K031/724, A61K031/426, A61K031/401, A61K031/366

514058000, 514369000, 514423000, 514460000, 514548000, 514458000, 514571000

Pharmaceutical compositions with synchronized solubilizer release as well as various methods associated therewith, are disclosed and described. More specifically, the aqueous solubility of a drug is enhanced by synchronized release of a solubilizer.

2003009, May 15, 2003

Mar 21, 2002

10/105032

David Fikstad - Salt Lake City UT, US
Charles Ebert - Yorba Linda CA, US
Srinivasan Venkateshwaran - So. Burlington VT, US
Lawrence Nilssen - Bountiful UT, US

A61K009/70

424/449000

A transdermal drug delivery system is disclosed, which includes a polymer, a drug and an amount of a quaternary ammonium salt that is sufficient to act as a penetration enhancer. The quaternary ammonium salt may also be present in an amount sufficient to act as an irritation reducer. Further, the transdermal drug delivery system may also contain a co-enhancer, which provides a synergistic skin permeation enhancing effect when combined with the quaternary ammonium salt. A method for enhancing the transdermal delivery of a drug is also disclosed.

5985317, Nov 16, 1999

Sep 6, 1996

8/706624

Srinivasan Venkateshwaran - Salt Lake City UT
David Fikstad - Salt Lake City UT
Charles D. Ebert - Salt Lake City UT

TheraTech, Inc. - Salt Lake City UT

A61L 1516

424449

A method of transdermally or transmucosally delivering a hydrophilic salt form of a drug with a water-based pressure sensitive hydrophobic adhesive matrix patch optionally containing a permeation enhancer is disclosed. A matrix patch comprising a water-based pressure sensitive hydrophobic adhesive, a hydrophilic salt form of a drug, and optionally a permeation enhancer for transdermal or transmucosal delivery of the hydrophilic salt form of the drug is also disclosed.